title: [A case of renal cell carcinoma complicated with interstitial pneumonitis, complete A-V block and pleural effusion during interferon-alpha therapy].
abstract: A 76-year-old man with postoperative renal cell carcinoma accompanied by multiple lung metastasis was being treated with recombinant interferon-alpha. After administration of 3 MU/day on 3 days/week for 1 month, he complained of headache and tinnitus. During continuous treatment for 3 months, he complained of appetite loss, low-grade fever and dyspnea. He was then referred to our Department of Internal Medicine. Electrocardiography indicated a complete A-V block, and chest radiography (CXR) showed a reticular shadow in both lower lung fields and bilateral pleural effusion. Chest computed tomography (CT) indicated subpleural emphysematous changes, multiple nodules, consolidation shadow with ground glass opacity in both lower lobes, and bilateral pleural effusion. The findings in the bronchoalveolar lavage (BAL) fluid included increases in the numbers of lymphocytes and eosinophils. We reached a diagnosis of interferon-alpha-induced pneumonitis on the basis of the patient's clinical course, and the CXR, chest CT and BAL fluid findings. Treatment with methylprednisolone pulse therapy for 3 days and then administration of prednisolone for 1 month resulted in marked improvement in the complete A-V block and interstitial pneumonitis. At day 7 after discontinuation of prednisolone, the serum level of C-reactive protein increased, and CXR showed bilateral pleural effusion. We therefore believe that the pleural effusion was probably also induced by interferon-alpha. Interferon is an effective drug for chronic hepatitis C and malignant diseases. Many complications have been reported during interferon therapy. However, although these complications, such as interstitial pneumonitis, complete A-V block and pleural effusion, have rarely been reported, careful attention is required during interferon therapy in case any appear.
authors.affiliation: First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Tsushima
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Furihata
authors.forename: J
authors.initials: J
authors.lastname: Hotta
authors.forename: M
authors.initials: M
authors.lastname: Sasabayashi
authors.forename: K
authors.initials: K
authors.lastname: Urushihata
authors.forename: S
authors.initials: S
authors.lastname: Takashi
authors.forename: A
authors.initials: A
authors.lastname: Tsukadaira
authors.forename: Y
authors.initials: Y
authors.lastname: Yamazaki
authors.forename: E
authors.initials: E
authors.lastname: Satou
authors.forename: M
authors.initials: M
authors.lastname: Hanaoka
authors.forename: T
authors.initials: T
authors.lastname: Koizumi
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ohkubo
authors.forename: K
authors.initials: K
authors.lastname: Kubo
mesh_terms: D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006327:Heart Block / Q000139:chemically induced*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D010996:Pleural Effusion / Q000139:chemically induced*
chemical_list: D016898:Interferon-alpha